Date Name Title Filing Type Shares Traded Price Total Held
Dec 13, 2013
Director, Pres Regeneron Labs
Director, Pres Regeneron Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 150,000 -- 246,736
Dec 14, 2012
Director, EVP CSO Pres Regen Res Labs
Director, EVP CSO Pres Regen Res Labs Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 150,000 -- 245,295
Dec 16, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 150,000 -- 244,048
Feb 19, 2019
Director, President and CSO
Director, President and CSO Form 4 Bona fide gift 150,722 -- 249,278
Feb 19, 2019
Director, President and CSO
Director, President and CSO Form 4 Bona fide gift 150,722 -- 753,316
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 158,079 $52.03 908,303
Dec 30, 2020
Director, President and Chief Scientific
Director, President and Chief Scientific Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 158,079 -- --
Dec 16, 2011
Director, EVP CSO President Regeneron Re
Director, EVP CSO President Regeneron Re Form 4 Grant, award or other acquisition pursuant to Rule 16b-3(d) 158,079 -- 158,079
Feb 15, 2024
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 172,723 $399.66 925,209
Feb 15, 2024
Director, Bd. Co-Chair, President & CSO
Director, Bd. Co-Chair, President & CSO Form 4 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 172,723 -- --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.